26 July 2022>: Original Paper
Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients
Karola Warzyszyńska 1ABCDEFG* , Michał Zawistowski 12BCDE , Edyta Karpeta 3B , Agnieszka Jałbrzykowska 4B , Maciej Kosieradzki 1DEDOI: 10.12659/AOT.936276
Ann Transplant 2022; 27:e936276
Table 1 Baseline demographics and clinicopathological characteristics of patients and brain-dead kidney donors.
Variable | All patientsN=95 | Subgroup (by donor CYP3A5 expression status) | Subgroup (by recipient CYP3A5 expression status) | ||
---|---|---|---|---|---|
D+ (n=16) | D− (n=79) | R+ (n=14) | R− (n=81) | ||
Donor gender: male | 66 (69.5) | 12 (75.0) | 54 (68.4) | 10 (10.0) | 56 (69.1) |
Donor age (years) | 45 [38–52] | 37.5 [35–46.75] | 47 [40–52] | 45 [42.25–51] | 45 [38–52] |
Donor BMI (kg/m) | 25.5 [23.1–28.4] | 23.1 [21.4–24.9] | 25.7 [23.7–28.7] | 25.0 [21.7–26.1] | 25.5 [23.6–28.4] |
Cause of death | |||||
Brain injury | 31 (32.6) | 4 (25.0) | 27 (34.2) | 6 (42.9) | 25 (30.9) |
Cardiovascular event | 54 (56.8) | 8 (50.0) | 46 (58.2) | 5 (35.7) | 49 (60.5) |
Other | 10 (10.5) | 4 (25.0) | 6 (7.6) | 3 (28.6) | 7 (8.6) |
Extended criteria donor | 6 (6.3) | 0 (0.0) | 6 (7.6) | 1 (7.1) | 5 (6.2) |
Non-scaled US KDRI | 2.58±0.48 | 2.51±0.45 | 2.59±0.49 | 2.60±0.46 | 2.57±0.49 |
Serum creatinine (mg/dL) | 1.04 [0.80–1.53] | 0.98 [0.81–1.31] | 1.08 [0.80–1.71] | 1.04 [0.84–1.34] | 1.04 [0.80–1.65] |
Patient gender: male | 66 (69.5) | 9 (56.3) | 57 (72.2) | 8 (57.1) | 58 (71.6) |
Patient age (years) | 43.8±11.1 | 46.7±10.9 | 43.3±11.2 | 39.6±10.9 | 44.6±11.1 |
Patient BMI (kg/m) | 24.3±3.8 | 26.2±3.9 | 23.9±3.7 | 23.9±3.3 | 24.4±3.9 |
Cause of CKD | |||||
Glomerulonephritis | 49 (51.6) | 7 (43.8) | 42 (53.2) | 9 (64.3) | 40 (49.4) |
ADPKD | 14 (14.7) | 1 (6.3) | 13 (16.5) | 1 (7.1) | 13 (16.1) |
Hypertensive nephropathy | 9 (9.5) | 1 (6.3) | 8 (10.1) | 0 (0.0) | 9 (11.1) |
Diabetic nephropathy | 5 (5.3) | 2 (12.5) | 3 (3.8) | 1 (7.1) | 4 (4.9) |
Other | 10 (10.5) | 3 (18.3) | 7 (8.9) | 2 (14.3) | 8 (9.9) |
Unknown | 8 (8.4) | 2 (12.5) | 6 (7.6) | 1 (7.1) | 7 (8.6) |
Retransplantation | 16 (16.8) | 5 (31.3) | 11 (13.9) | 1 (7.1) | 15 (18.5) |
Maximal PRA >0% | 25 (26.3) | 5 (33.3) | 20 (25.6) | 5 (35.7) | 20 (25.3) |
Pre-transplant PRA >0% | 14 (14.7) | 3 (20.0) | 11 (14.1) | 2 (14.3) | 12 (15.2) |
HLA mismatches | |||||
0–2 | 44 (46.3) | 8 (50.0) | 36 (45.6) | 5 (35.7) | 39 (48.2) |
3–4 | 45 (47.4) | 8 (50.0) | 37 (46.8) | 7 (50.0) | 38 (46.9) |
5–6 | 6 (6.3) | 0 (0.0) | 6 (7.6) | 2 (14.3) | 4 (4.9) |
Induction immunosuppression | 43 (45.3) | 11 (68.8) | 31 (39.7) | 7 (50.0) | 35 (43.8) |
Categorical variables reported as number (%) and assessed using the chi-squared or Fisher’s exact test (expected n < 5). Continuous data reported as median [Q1–Q3] or mean±SD based on the normality of data, and evaluated using Mann-Whitney U or test, as appropriate. D+ – donor CYP3A5 expressor; D− – donor CYP3A5 non-expressor; R+ – recipient CYP3A5 expressor; R− – recipient CYP3A5 non-expressor; KDRI – unscaled US Kidney Donor Risk Index; ADPKD – autosomal dominant polycystic kidney disease; PRA – panel reactive antibody; SD – standard deviation. |